ArticleCancer immunology, immunotherapy : CII2026
Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
B cells have become one of the important participants in anti-tumor immunity. Compared with DCs and macrophages, B cells have unique advantages in presenting low-abundance antigens to T cells. Fatty acids play a key role in the metabolic adaptation of B cells. Whether the APC function of B cells can be enhanced through reprogramming fatty acid metabolism in the tumor microenvironment (TME) is worthy of study. Ovarian cancer (OvCa) is a gynecological malignant tumor with a high mortality rate. Most patients in the advanced stage often have extensive omental metastasis and ascites formation, which are rich in adipocytes and fatty acids. Given reasons including complex TME, the clinical efficacy of new immunotherapies such as immune checkpoint blockade (ICB) therapy for OvCa is very limited. Therefore, treatment regimens based on new mechanisms are urgently needed to be developed. In this study, we applied the Gene Expression Omnibus (GEO) database, clinical specimens, cell lines, and mouse models to investigate whether reprogramming the fatty acid metabolism in B cells could enhance their APC function and to explore the underlying mechanisms. We also evaluated the therapeutic effects of the combined treatment using APC-enhanced-B cells adoption with low-dose chemotherapy in metastatic OvCa mice. Our research provides new clues forB cells-based anti-tumor immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.